SecBot SecBot
8-K ·Filed Aug 6, 2026

LXRX

LEXICON PHARMACEUTICALS, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago SEC0001062822-26-000112
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on pipeline catalysts rather than quarterly financials. Key binary events to watch: ZYNQUISTA NDA resubmission (Q4 2026) and SONATA-HCM topline data (Q1 2027). The $190.6M cash position funds operations through these milestones. Monitor for potential $10M milestone payment from Novo Nordisk later this year.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

LXRX drug pipeline →

ZYNQUISTA

◆ Mixed Named in this 8-K
Impact
Phase
Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
Time to market
Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
Next catalyst
None dated

What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.

Price Chart

Loading chart...

Executive Summary

Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2025 which included a $27.6M licensing milestone from Novo Nordisk. Net loss widened to $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) a year ago. The quarter's focus was on pipeline execution: SONATA-HCM enrollment completed on time (topline Q1 2027), ZYNQUISTA NDA resubmission expected Q4 2026, and cash position of $190.6M provides runway through key catalysts.

Key Financial Metrics

EPS
−$0.07
est −$0.05 · -40.0%
Revenue
$692.0K
est $4.0M · -82.7% · -97.6% YoY
Rating
in line

Key Facts

  • Total revenue Q2 2026: $0.7M vs $28.9M in Q2 2025 (prior year included $27.6M Novo Nordisk milestone)
  • Net loss Q2 2026: $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) in Q2 2025
  • SONATA-HCM Phase 3 enrollment completed, substantially exceeding 500-patient target; topline data expected Q1 2027
  • ZYNQUISTA NDA resubmission for type 1 diabetes anticipated in Q4 2026
  • Cash and investments: $190.6M as of June 30, 2026, up from $125.2M at Dec 31, 2025
  • R&D expenses increased to $17.4M from $15.7M, driven by SONATA-HCM trial costs
  • Loss on early extinguishment of debt: $4.3M in Q2 2026

Financial Impact

Revenue declined 97.6% YoY due to absence of prior-year licensing milestone; net loss of $31.8M vs prior-year net income of $3.3M; cash burn of ~$35M in H1 2026

revenuenet incomecash

Risk Factors

  • ZYNQUISTA NDA resubmission may face delays or additional FDA data requirements
  • SONATA-HCM topline results could miss efficacy endpoints
  • Cash burn rate may require additional financing before reaching profitability
  • INPEFA commercial revenue remains minimal at $0.7M/quarter

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062822-26-000112
Document: lxrx-20260806.htm0001062822-26-000112
Document: 0001062822-26-000112-index-headers.html0001062822-26-000112
Document: 0001062822-26-000112-index.html0001062822-26-000112
Document: 0001062822-26-000112.txt0001062822-26-000112
8-K Data (Synthetic)0001062822-26-000112

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 Viewing No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026